Study Overview
Ostojic (2016) investigated guanidinoacetate (GAA) as a direct precursor to creatine, exploring whether supplementing with GAA could effectively increase creatine levels through the body’s endogenous synthesis pathway.
This research examines an alternative approach to raising creatine stores, leveraging the body’s natural creatine biosynthesis machinery .
Key Findings
- GAA increased creatine levels: Supplementation with guanidinoacetate effectively raised serum creatine and phosphocreatine concentrations, confirming its role as a functional creatine precursor
- Methylation demand: GAA supplementation increased demand for methyl groups (from SAM — S-adenosylmethionine), which raised homocysteine levels as a metabolic byproduct
- Dose-dependent effects: The creatine-raising effect of GAA was dose-dependent, with higher doses producing greater increases in creatine but also greater homocysteine elevation
- Potential for creatine deficiency syndromes: GAA may have specific utility in certain creatine deficiency syndromes where the biosynthetic pathway can be targeted
- Lower molecular weight: GAA has a lower molecular weight than creatine, theoretically allowing better absorption, though this advantage must be weighed against safety considerations
Practical Implications
For the vast majority of individuals, creatine monohydrate remains the gold standard supplement.
Ostojic’s research on GAA is scientifically important for understanding creatine biosynthesis and may have niche clinical applications, but it does not change the practical recommendation for healthy individuals.
The elevation of homocysteine — a cardiovascular risk marker — is a significant concern that makes GAA supplementation less attractive than direct creatine supplementation for general use.
Creatine monohydrate bypasses the methylation step entirely, providing creatine directly without the homocysteine trade-off.
This research is most relevant for scientists studying creatine metabolism and clinicians treating creatine deficiency syndromes.
Study Limitations
- Safety data on long-term GAA supplementation is limited compared to the extensive creatine monohydrate literature
- The homocysteine elevation is a clinically relevant concern that has not been adequately addressed in long-term studies
- Most data comes from small studies and may not generalize broadly
- Head-to-head comparisons between GAA and creatine monohydrate at equivalent effective doses are limited
- GAA products are not widely available or regulated to the same standard as creatine monohydrate
Where This Fits in the Evidence
Ostojic (2016) approaches creatine status from the supply side, asking whether feeding the precursor guanidinoacetate can raise serum and muscle creatine through the body’s own synthesis pathway. It can — but the same methylation step that converts GAA to creatine also elevates homocysteine, a trade-off that plain creatine monohydrate avoids entirely. That cost is why this work matters most for understanding biosynthesis and rare creatine deficiency syndromes rather than for everyday supplementation. For how monohydrate became the default reference form, see the ISSN position stand, and for the surrounding evidence our research library.
Sources & References
This page summarizes Ostojic (2016). Full citation: Ostojic SM.
Guanidinoacetic acid as a performance-enhancing agent. Amino Acids. 2016;48(8):1867-1875. doi:10.1007/s00726-015-2106-y
What This Means for You
The practical conclusion here is to stick with creatine monohydrate. Guanidinoacetate can raise your creatine levels, but it does so by leaning on the body’s methylation step, which pushes up homocysteine — a cardiovascular risk marker that plain monohydrate sidesteps entirely. Unless you are dealing with a specific creatine-synthesis disorder under medical care, there is no everyday reason to choose the precursor over the cheaper, better-studied and safer monohydrate.